EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study

Salvatore Mazzeo iD, Assunta Ingannato, Giulia Giacomucci, Alberto Manganelli, Valentina Moschini, Juri Balestrini, Arianna Cavaliere, Carmen Morinelli, Giulia Galdo, Filippo Emiliani, Diletta Piazzesi, Chiara Crucitti und 8 weitere

European Journal of Neurology · 2024

DOI: 10.1111/ene.16089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Salvatore Mazzeo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Neurofilament Proteins. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute, Regione Toscana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).

Methods

This longitudinal cohort study involved 140 patients (45 with SCD, 73 with MCI, and 22 with AD dementia [AD‐D]) who underwent plasma NfL and AD biomarker assessments (cerebrospinal fluid, amyloid positron emission tomography [PET], and 18 F‐fluorodeoxyglucose‐PET) at baseline. The patients were rated according to the amyloid/tau/neurodegeneration (A/T/N) system and followed up for a mean time of 2.72 ± 0.95 years to detect progression from SCD to MCI and from MCI to AD. Forty‐eight patients (19 SCD, 29 MCI) also underwent plasma NfL measurements 2 years after baseline.

Results

At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N−) with high accuracy (area under the curve [AUC] 0.82). We identified cut‐off values of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow‐up, nine SCD patients progressed to MCI (progressive SCD [p‐SCD]), and 14 MCI patients developed AD dementia (progressive MCI [p‐MCI]). The previously identified cut‐off values provided good accuracy in identifying p‐SCD (80% [95% confidence interval 65.69: 94.31]). The rate of NfL change was higher in p‐MCI (3.52 ± 4.06 pg/mL) compared to non‐progressive SCD (0.81 ± 1.25 pg/mL) and non‐progressive MCI (−0.13 ± 3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC 0.954).

Conclusion

Plasma NfL concentration and change over time may be a reliable, non‐invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionNeurofilament ProteinsHumansAmyloid beta-PeptidesBiomarkersCross-Sectional StudiesDisease ProgressionIntermediate FilamentsLongitudinal Studiestau Proteins

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkerdementiamild cognitive impairmentneurofilament

Substanzen

Amyloid beta-PeptidesBiomarkerstau Proteinsneurofilament protein LNeurofilament Proteins

Autor:innen und Institutionen

  • Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
  • Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
  • IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
  • Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
  • Regional Referral Centre for Relational Criticalities - 50139, Tuscany Region, Italy.

ORCID-Profile: Salvatore Mazzeo, Valentina Berti, Valentina Bessi

Förderung

  • Ministero della Salute
  • Regione Toscana

Zitieren

APA

Mazzeo, S., Ingannato, A., Giacomucci, G., Manganelli, A., Moschini, V., Balestrini, J., Cavaliere, A., Morinelli, C., Galdo, G., Emiliani, F., Piazzesi, D., Crucitti, C., Frigerio, D., Polito, C., Berti, V., Bagnoli, S., Padiglioni, S., Sorbi, S., Nacmias, B., & Bessi, V. (2024). Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study. European Journal of Neurology. https://doi.org/10.1111/ene.16089

Vancouver

Mazzeo S, Ingannato A, Giacomucci G, Manganelli A, Moschini V, Balestrini J, et al. Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study. European Journal of Neurology. 2024. doi:10.1111/ene.16089

BibTeX
@article{Mazzeo2024,
  author = {Mazzeo, Salvatore and Ingannato, Assunta and Giacomucci, Giulia and Manganelli, Alberto and Moschini, Valentina and Balestrini, Juri and Cavaliere, Arianna and Morinelli, Carmen and Galdo, Giulia and Emiliani, Filippo and Piazzesi, Diletta and Crucitti, Chiara and Frigerio, Daniele and Polito, Cristina and Berti, Valentina and Bagnoli, Silvia and Padiglioni, Sonia and Sorbi, Sandro and Nacmias, Benedetta and Bessi, Valentina},
  title = {Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16089}
}
Kostenlos starten →